Ionis Pharmaceuticals (IONS) Revenue & Revenue Breakdown
Ionis Pharmaceuticals Revenue Highlights
Latest Revenue (Y)
$787.65M
Latest Revenue (Q)
$225.00M
Main Segment (Y)
Research and Development Revenue
Ionis Pharmaceuticals Revenue by Period
Ionis Pharmaceuticals Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | $787.65M | 34.18% |
| 2022-12-31 | $587.00M | -27.53% |
| 2021-12-31 | $810.00M | 11.11% |
| 2020-12-31 | $729.00M | -35.08% |
| 2019-12-31 | $1.12B | 87.27% |
| 2018-12-31 | $599.67M | 18.12% |
| 2017-12-31 | $507.67M | 46.46% |
| 2016-12-31 | $346.62M | 22.18% |
| 2015-12-31 | $283.70M | 32.47% |
| 2014-12-31 | $214.16M | 45.41% |
| 2013-12-31 | $147.28M | 44.33% |
| 2012-12-31 | $102.05M | 2.99% |
| 2011-12-31 | $99.09M | -8.65% |
| 2010-12-31 | $108.47M | -10.80% |
| 2009-12-31 | $121.60M | 13.44% |
| 2008-12-31 | $107.19M | 53.96% |
| 2007-12-31 | $69.62M | 183.80% |
| 2006-12-31 | $24.53M | -38.87% |
| 2005-12-31 | $40.13M | -5.84% |
| 2004-12-31 | $42.62M | -14.73% |
| 2003-12-31 | $49.99M | -37.65% |
| 2002-12-31 | $80.18M | 50.51% |
| 2001-12-31 | $53.27M | 43.00% |
| 2000-12-31 | $37.26M | 9.90% |
| 1999-12-31 | $33.90M | -13.52% |
| 1998-12-31 | $39.20M | 20.62% |
| 1997-12-31 | $32.50M | 43.81% |
| 1996-12-31 | $22.60M | 73.85% |
| 1995-12-31 | $13.00M | 28.71% |
| 1994-12-31 | $10.10M | -16.53% |
| 1993-12-31 | $12.10M | - |
Ionis Pharmaceuticals generated $787.65M in revenue during NA 2023, up 34.18% compared to the previous quarter, and up 131.35% compared to the same period a year ago.
Ionis Pharmaceuticals Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-06-30 | $225.00M | 88.29% |
| 2024-03-31 | $119.50M | -63.18% |
| 2023-12-31 | $324.50M | 125.35% |
| 2023-09-30 | $144.00M | -23.40% |
| 2023-06-30 | $188.00M | 43.51% |
| 2023-03-31 | $131.00M | -13.82% |
| 2022-12-31 | $152.00M | -4.86% |
| 2022-09-30 | $159.77M | 19.42% |
| 2022-06-30 | $133.79M | -5.73% |
| 2022-03-31 | $141.92M | -67.75% |
| 2021-12-31 | $440.00M | 230.60% |
| 2021-09-30 | $133.09M | 5.84% |
| 2021-06-30 | $125.75M | 12.67% |
| 2021-03-31 | $111.61M | -61.51% |
| 2020-12-31 | $290.00M | 81.16% |
| 2020-09-30 | $160.08M | 9.99% |
| 2020-06-30 | $145.54M | 9.13% |
| 2020-03-31 | $133.37M | -73.00% |
| 2019-12-31 | $494.00M | 194.24% |
| 2019-09-30 | $167.89M | 2.37% |
| 2019-06-30 | $164.00M | -44.82% |
| 2019-03-31 | $297.21M | 54.71% |
| 2018-12-31 | $192.11M | 32.13% |
| 2018-09-30 | $145.40M | 23.48% |
| 2018-06-30 | $117.75M | -18.47% |
| 2018-03-31 | $144.42M | -16.18% |
| 2017-12-31 | $172.30M | 42.50% |
| 2017-09-30 | $120.91M | 16.09% |
| 2017-06-30 | $104.15M | -5.58% |
| 2017-03-31 | $110.30M | -31.21% |
| 2016-12-31 | $160.35M | 44.55% |
| 2016-09-30 | $110.93M | 188.35% |
| 2016-06-30 | $38.47M | 4.33% |
| 2016-03-31 | $36.87M | -28.50% |
| 2015-12-31 | $51.57M | 4.99% |
| 2015-09-30 | $49.12M | -59.21% |
| 2015-06-30 | $120.43M | 92.43% |
| 2015-03-31 | $62.58M | -26.25% |
| 2014-12-31 | $84.86M | 92.59% |
| 2014-09-30 | $44.06M | -22.80% |
| 2014-06-30 | $57.08M | 102.68% |
| 2014-03-31 | $28.16M | -33.35% |
| 2013-12-31 | $42.25M | 79.14% |
| 2013-09-30 | $23.59M | -38.08% |
| 2013-06-30 | $38.09M | -12.15% |
| 2013-03-31 | $43.36M | 118.19% |
| 2012-12-31 | $19.87M | 71.30% |
| 2012-09-30 | $11.60M | -75.49% |
| 2012-06-30 | $47.34M | 103.74% |
| 2012-03-31 | $23.23M | -28.29% |
| 2011-12-31 | $32.40M | 56.44% |
| 2011-09-30 | $20.71M | -16.56% |
| 2011-06-30 | $24.82M | 17.38% |
| 2011-03-31 | $21.15M | -19.96% |
| 2010-12-31 | $26.42M | -7.70% |
| 2010-09-30 | $28.62M | 21.79% |
| 2010-06-30 | $23.50M | -21.46% |
| 2010-03-31 | $29.93M | -7.24% |
| 2009-12-31 | $32.26M | 20.51% |
| 2009-09-30 | $26.77M | -13.62% |
| 2009-06-30 | $30.99M | -1.85% |
| 2009-03-31 | $31.58M | 52.83% |
| 2008-12-31 | $20.66M | -35.87% |
| 2008-09-30 | $32.22M | -2.26% |
| 2008-06-30 | $32.96M | 54.36% |
| 2008-03-31 | $21.35M | -13.64% |
| 2007-12-31 | $24.73M | - |
Ionis Pharmaceuticals generated $225.00M in revenue during Q2 2024, up 88.29% compared to the previous quarter, and up 171.76% compared to the same period a year ago.
Ionis Pharmaceuticals Revenue Breakdown
Ionis Pharmaceuticals Revenue Breakdown by Product
Annual Revenue by Product
| Product/Service | Dec 23 | Dec 22 | Dec 21 | Dec 20 | Dec 19 |
|---|---|---|---|---|---|
| SPINRAZA Royalties | $240.38M | $292.99M | - | - | - |
| Licensing and Other Royalties | $33.30M | $30.99M | $19.12M | $8.12M | $17.20M |
| Other Commercial | $68.21M | - | - | - | - |
| Product | $34.91M | $30.05M | $70.00M | $42.25M | - |
| Research and Development Revenue | $479.06M | $284.01M | - | - | - |
| Commercial | $308.59M | $303.36M | $342.39M | $364.70M | $352.45M |
| Collaborative Agreement Revenue | $352.66M | $207.22M | - | - | - |
| Spinraza Royalties | - | $242.31M | $267.78M | $286.58M | - |
| Eplontersen Joint Development Revenue | - | $76.79M | - | - | - |
| Research and Development Revenue Under Collaborative Agreements | - | - | $468.06M | $364.56M | $770.15M |
| TEGSEDI and WAYLIVRA | - | - | $55.50M | - | - |
Ionis Pharmaceuticals's latest annual revenue breakdown by segment (product or service), as of Dec 23: Research and Development Revenue (31.58%), Collaborative Agreement Revenue (23.25%), Commercial (20.34%), SPINRAZA Royalties (15.84%), Other Commercial (4.50%), Product (2.30%), and Licensing and Other Royalties (2.19%).
Quarterly Revenue by Product
| Product/Service | Jun 24 | Dec 23 | Sep 23 | Jun 23 |
|---|---|---|---|---|
| Collaborative Agreement Revenue | $141.52M | $179.14M | $44.17M | $91.01M |
| Commercial | $72.04M | $78.84M | $84.08M | $77.90M |
| Licensing and Other Royalties | $3.32M | $13.71M | $8.54M | - |
| Other Commercial | $11.51M | $34.50M | $16.83M | $16.89M |
| Product | $8.19M | $20.15M | $8.29M | - |
| Research and Development Revenue | $153.21M | $245.66M | $60.13M | $110.51M |
| SPINRAZA Royalties | $56.74M | $112.11M | $67.25M | $61.01M |
| Eplontersen Joint Development Revenue | - | - | $15.96M | $19.50M |
Ionis Pharmaceuticals's latest quarterly revenue breakdown by segment (product or service), as of Jun 24: Research and Development Revenue (34.31%), Collaborative Agreement Revenue (31.69%), Commercial (16.13%), SPINRAZA Royalties (12.71%), Other Commercial (2.58%), Product (1.83%), and Licensing and Other Royalties (0.74%).
Ionis Pharmaceuticals Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| INCY | Incyte | $3.70B | $1.04B |
| BMRN | BioMarin Pharmaceutical | $2.42B | $712.03M |
| EXEL | Exelixis | $1.83B | $637.18M |
| ALNY | Alnylam Pharmaceuticals | $1.83B | $659.83M |
| SRPT | Sarepta Therapeutics | $1.24B | $413.46M |
| PTCT | PTC Therapeutics | $937.82M | $186.70M |
| HALO | Halozyme Therapeutics | $829.25M | $231.35M |
| IONS | Ionis Pharmaceuticals | $787.65M | $225.00M |
| APLS | Apellis Pharmaceuticals | $366.28M | $179.14M |
| ARWR | Arrowhead Pharmaceuticals | $240.74M | - |
| KRYS | Krystal Biotech | $50.70M | $70.28M |
| IOVA | Iovance Biotherapeutics | $1.19M | $31.11M |
| VKTX | Viking Therapeutics | - | - |
| MDGL | Madrigal Pharmaceuticals | - | - |
| TERN | Terns Pharmaceuticals | - | - |
| AKRO | Akero Therapeutics | - | - |
IONS Revenue FAQ
What is Ionis Pharmaceuticals’s yearly revenue?
Ionis Pharmaceuticals's yearly revenue for 2023 was $787.65M, representing an increase of 34.18% compared to 2022. The company's yearly revenue for 2022 was $587M, representing a decrease of -27.53% compared to 2021. IONS's yearly revenue for 2021 was $810M, representing an increase of 11.11% compared to 2020.
What is Ionis Pharmaceuticals’s quarterly revenue?
Ionis Pharmaceuticals's quarterly revenue for Q2 2024 was $225M, a 88.29% increase from the previous quarter (Q1 2024), and a 19.68% increase year-over-year (Q2 2023). The company's quarterly revenue for Q1 2024 was $119.5M, a -63.18% decrease from the previous quarter (Q4 2023), and a -8.78% decrease year-over-year (Q1 2023). IONS's quarterly revenue for Q4 2023 was $324.5M, a 125.35% increase from the previous quarter (Q3 2023), and a 113.49% increase year-over-year (Q4 2022).
What is Ionis Pharmaceuticals’s revenue growth rate?
Ionis Pharmaceuticals's revenue growth rate for the last 3 years (2021-2023) was -2.76%, and for the last 5 years (2019-2023) was -29.86%.
What are Ionis Pharmaceuticals’s revenue streams?
Ionis Pharmaceuticals's revenue streams in c 23 are SPINRAZA Royalties, Licensing and Other Royalties, Other Commercial, Product, Research and Development Revenue, Commercial, and Collaborative Agreement Revenue. SPINRAZA Royalties generated $240.38M in revenue, accounting 15.84% of the company's total revenue, down -17.96% year-over-year. Licensing and Other Royalties generated $33.3M in revenue, accounting 2.19% of the company's total revenue, up 7.44% year-over-year. Other Commercial generated $68.21M in revenue, accounting 4.50% of the company's total revenue Product generated $34.91M in revenue, accounting 2.30% of the company's total revenue, up 16.18% year-over-year. Research and Development Revenue generated $479.06M in revenue, accounting 31.58% of the company's total revenue, up 68.68% year-over-year. Commercial generated $308.59M in revenue, accounting 20.34% of the company's total revenue, up 1.73% year-over-year. Collaborative Agreement Revenue generated $352.66M in revenue, accounting 23.25% of the company's total revenue, up 70.18% year-over-year.
What is Ionis Pharmaceuticals’s main source of revenue?
For the fiscal year ending Dec 23, the largest source of revenue of Ionis Pharmaceuticals was Research and Development Revenue. This segment made a revenue of $479.06M, representing 31.58% of the company's total revenue.